Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
ALK-Abelló A/S |
---|---|
Information provided by: | ALK-Abelló A/S |
ClinicalTrials.gov Identifier: | NCT00310466 |
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
Condition | Intervention | Phase |
---|---|---|
Allergy |
Biological: Sublingual immunotherapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicentre, Randomised, Double-Blind,Placebo-Controlled Parallel Group Clinical Trial to Investigate the Efficacy and Safety of Specific Sublingual Immunotherapy With SLIT One Birch in Patients With Seasonal Birch Pollen Induced Rhinoconjunctivitis |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Charité Klinik für Dermatologie, Venerologie und Allergologie | |
Berlin, Germany, D-10117 |
Study Director: | Hendrik Wolf, PhD | ALK-SCHERAX Arzneimittel GmbH |
Principal Investigator: | Margitta Worm, MD, Prof. | Charité, Berlin |
Study ID Numbers: | SHX0712 |
Study First Received: | April 2, 2006 |
Last Updated: | March 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00310466 History of Changes |
Health Authority: | Germany: Paul-Ehrlich-Institut |
Hypersensitivity Rhinitis, Allergic, Seasonal |